Naltrexone Neuroimaging in Teens With Eating Disorders
Key facts
- Who runs it
- Children's Mercy Hospital Kansas City
- Where
- Kansas City, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 60 people, planned
- Started
- 17 Sept 2022
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Naltrexone
- Placebo
- Record updated
- 16 October 2026
Who can take part
- Age
- 13 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adolescents and young adults aged 13-21 years
- Eating disorder diagnosis characterized by binge eating and/or purging (eg, Anorexia Nervosa-Binge/Purge, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding/Eating Disorder) using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria
- Stable medication regimen (no dose or drug changes in the past 4 weeks)
- Participant and parent/legal guardian (if under 18 years) are willing and able to provide informed permission/assent/consent for the study
Who cannot take part
- Prior hypersensitivity reaction to naltrexone (e.g., anaphylaxis)
- Pregnant (via UCG)
- Non-removable metal in the body that is magnetic resonance imaging incompatible
- Current naltrexone use
- Self-reported opioid use in the past 7 days
- A language barrier (e.g., non-English speaking) for the participant that precludes communication and/or ability to complete all study-related requirements
Where in United States
- Children's Mercy Research InstituteKansas City, United States
About the trial
What the trial wants to find out
Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).
The 2 groups in the trial
- Group ATreatment being tested
All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.
Treatment: Naltrexone and Placebo
- Group BTreatment being tested
All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.
Treatment: Naltrexone and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
- Record updated
- 16 October 2026